1.Bone mineral density and infl ammatory and bone biomarkers after darunavir–ritonavir combined with either raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. J I Bernardino, A Mocroft, P W Mallon, C Wallet, J Gerstoft, C Russell, P Reiss, C Katlama, S De Wit, L Richert, A Babiker, A Buño, A Castagna, P Girard, G Chene, F Raffi , J R Arribas, for the NEAT001/ANRS143 Study Group*.        
The Lancet HIV. Published Online September 30, 2015. S2352-3018(15)00181-2. abstract

2.Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy. A Winston, J ,W Stöhr , A Arenas-Pinto, JM Llibre, H Amieva , A Cabié , I Williams, G De Perri, M J Tellez , J Rockstroh, A Babiker, A Pozniak , F Raffi, and L Richert for the NEAT 001/Agence Nationale de Recherche sur le SIDA (ANRS) 143 Study Group.
HIV Med.2015 Nov 26.doi:10.1111/hiv.12344. (Epub ahead of print) abstract

3. NtRTI sparing in patients at risk of bone disease. C Orkin, A  Umaipalan.
Lancet HIV 2015 Nov 2 (11). abstract


Does HIV antiretroviral therapy still need its backbone? M Battegay , L Elzi 
Lancet. 2014 Nov 29;384(9958):1908-10. doi: 10.1016/S0140-6736(14)61226-5. abstract

Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.F Raffi , AG Babiker , LRichert ,JM  Molina , EC George , A Antinori , JR Arribas ,J  Grarup , F Hudson ,C  Schwimmer , J Saillard , C Wallet , PO Jansson , C Allavena , R Van Leeuwen , JF Delfraissy , S Vella , G Chêne , A Pozniak ; NEAT001/ANRS143 Study Group
Lancet. 2014 Nov 29;384(9958):1942-51. doi: 10.1016/S0140-6736(14)61170-3. Epub 2014 Aug 4.abstract